107 related articles for article (PubMed ID: 26595150)
1. Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Burchall GF; Piva TJ; Linden MD; Gibson-Helm ME; Ranasinha S; Teede HJ
Semin Thromb Hemost; 2016 Feb; 42(1):55-62. PubMed ID: 26595150
[TBL] [Abstract][Full Text] [Related]
2. Differential Effects on Haemostatic Markers by Metformin and the Contraceptive Pill: A Randomized Comparative Trial in PCOS.
Burchall GF; Piva TJ; Ranasinha S; Teede HJ
Thromb Haemost; 2017 Nov; 117(11):2053-2062. PubMed ID: 29202210
[No Abstract] [Full Text] [Related]
3. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
Moran LJ; Hutchison SK; Meyer C; Zoungas S; Teede HJ
Clin Sci (Lond); 2009 May; 116(10):761-70. PubMed ID: 18851710
[TBL] [Abstract][Full Text] [Related]
4. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
Mannerås-Holm L; Baghaei F; Holm G; Janson PO; Ohlsson C; Lönn M; Stener-Victorin E
J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248
[TBL] [Abstract][Full Text] [Related]
5. Android fat distribution affects some hemostatic parameters in women with polycystic ovary syndrome compared with healthy control subjects matched for age and body mass index.
de Mendonça-Louzeiro MR; Annichino-Bizzacchi JM; Benetti-Pinto CL
Fertil Steril; 2015 Aug; 104(2):467-73. PubMed ID: 26051101
[TBL] [Abstract][Full Text] [Related]
6. Increased Coagulation and Decreased Fibrinolysis as Measured with Overall Hemostatic Potential Are Dependent on BMI and Not Associated with PCOS.
Rakusa M; Jensterle M; Božič-Mijovski M; Janez A
Metab Syndr Relat Disord; 2017 May; 15(4):194-198. PubMed ID: 28287900
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
Lindholm A; Bixo M; Eliasson M; Hudecova M; Arnadottir R; Holte J; Poromaa IS
Gynecol Endocrinol; 2010 Oct; 26(10):743-8. PubMed ID: 20500107
[TBL] [Abstract][Full Text] [Related]
8. Vascular function in the diagnostic categories of polycystic ovary syndrome.
Moran LJ; Cameron JD; Strauss BJ; Teede HJ
Hum Reprod; 2011 Aug; 26(8):2192-9. PubMed ID: 21616917
[TBL] [Abstract][Full Text] [Related]
9. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
[TBL] [Abstract][Full Text] [Related]
10. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
Morales AJ; Laughlin GA; Bützow T; Maheshwari H; Baumann G; Yen SS
J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
[TBL] [Abstract][Full Text] [Related]
11. The effect of diet and exercise on markers of endothelial function in overweight and obese women with polycystic ovary syndrome.
Thomson RL; Brinkworth GD; Noakes M; Clifton PM; Norman RJ; Buckley JD
Hum Reprod; 2012 Jul; 27(7):2169-76. PubMed ID: 22552687
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Glueck CJ; Sieve L; Zhu B; Wang P
Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878
[TBL] [Abstract][Full Text] [Related]
13. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?
Orio F; Palomba S; Cascella T; Tauchmanovà L; Nardo LG; Di Biase S; Labella D; Russo T; Savastano S; Tolino A; Zullo F; Colao A; Lombardi G
Reprod Biomed Online; 2004 Nov; 9(5):505-10. PubMed ID: 15588467
[TBL] [Abstract][Full Text] [Related]
14. Detailed characterisation of circulatory nitric oxide and free radical indices--is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome?
Willis GR; Udiawar M; Evans WD; Blundell HL; James PE; Rees DA
BJOG; 2014 Dec; 121(13):1596-603. PubMed ID: 24816317
[TBL] [Abstract][Full Text] [Related]
15. Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome.
Targher G; Zoppini G; Bonora E; Moghetti P
Semin Thromb Hemost; 2014 Jul; 40(5):600-18. PubMed ID: 25000958
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
17. Serum retinol-binding protein 4, leptin, and plasma asymmetric dimethylarginine levels in obese and nonobese young women with polycystic ovary syndrome.
Yildizhan R; Ilhan GA; Yildizhan B; Kolusari A; Adali E; Bugdayci G
Fertil Steril; 2011 Jul; 96(1):246-50. PubMed ID: 21600576
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic abnormalities and relationships to metabolic and hormonal status in polycystic ovarian syndrome.
Burchall G; Linden MD; Teede H; Piva TJ
Trends Cardiovasc Med; 2011 Jan; 21(1):6-14. PubMed ID: 22498014
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of asymmetric dimethylarginine, nitric oxide levels and associated independent variables in obese and lean patients with polycystic ovarian syndrome.
Türkçüoğlu I; Engin-Üstün Y; Turan F; Kali Z; Karabulut AB; Meydanli M; Kafkasli A
Gynecol Endocrinol; 2011 Sep; 27(9):609-14. PubMed ID: 20695761
[TBL] [Abstract][Full Text] [Related]
20. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome.
Oral B; Mermi B; Dilek M; Alanoğlu G; Sütçü R
Gynecol Endocrinol; 2009 Feb; 25(2):110-6. PubMed ID: 19253106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
